The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity <it>in vitro</it>: a mechanism of action study

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity <it>in vitro</it>: a mechanism of action study

<p>Abstract</p> <p>Background</p> <p>Tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) are the three components of the once-daily, single tablet regimen (Atripla) for treatment of HIV-1 infection. Previous cell culture studies have demonstrat...

Full description

Bibliographic Details
Main Authors:	Svarovskaia Evguenia S, White Kirsten L, Goodman Derrick, Myrick Florence, Ly John K, Feng Joy Y, Borroto-Esoda Katyna, Miller Michael D
Format:	Article
Language:	English
Published:	BMC 2009-05-01
Series:	Retrovirology
Online Access:	http://www.retrovirology.com/content/6/1/44

Similar Items

Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC
by: Arun Ramaswamy, et al.
Published: (2018-02-01)

A Comparison between the Efficiency of Vonavir (Tenofovir-Emtricitabine- Efavirenz) and Cobavir (Lamivudine-Zidovudine) with Efavirenz used for HIV Patients in Fasa, Iran
by: Saeideh Honarmand, et al.
Published: (2022-07-01)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
by: Juday T, et al.
Published: (2013-09-01)

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
by: Graeme J Moyle, et al.
Published: (2015-01-01)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
by: Yongquan Peng, et al.
Published: (2023-11-01)

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
by: Cao Jing, et al.
Published: (2023-06-01)

Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
by: Huan Xia, et al.
Published: (2021-12-01)

Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
by: Wei-Chieh Huang, et al.
Published: (2021-10-01)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
by: Oliver T. Stirrup, et al.
Published: (2019-10-01)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
by: Eric H. Decloedt, et al.
Published: (2021-04-01)

Effectiveness of tenofovir/emtricitabine versus zidovudine/lamivudine in combination with efavirenz in antiretro viral-naive HIV infected patients / Siti Mahanim Shaik Ismail
by: Shaik Ismail, Siti Mahanim
Published: (2015)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
by: Bernardini C, et al.
Published: (2013-06-01)

Bictegravir, Emtricitabine & Tenofovir Alafenamide-associated Acute Pancreatitis
by: Abdulmajeed Alharbi
Published: (2023-05-01)

Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats.
by: Frans Everson, et al.
Published: (2018-01-01)

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
by: Xinhui Chen, et al.
Published: (2016-01-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023-12-01)

Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV
by: Sara Iannuzzi, et al.
Published: (2021-07-01)

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
by: Bruno Emond, et al.
Published: (2021-06-01)

The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2
by: Joy Y. Feng, et al.
Published: (2022-06-01)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)<sub>2 </sub>vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
by: Focà Emanuele, et al.
Published: (2012-02-01)

Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
by: Franco Maggiolo, et al.
Published: (2022-11-01)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015-09-01)

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.
by: J Gerardo García-Lerma, et al.
Published: (2008-02-01)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
by: Januszka JE, et al.
Published: (2023-11-01)

Evaluation of Rapidly Disintegrating Vaginal Tablets of Tenofovir, Emtricitabine and Their Combination for HIV-1 Prevention
by: Meredith R. Clark, et al.
Published: (2014-12-01)

Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion
by: Shui-Shan Lee, et al.
Published: (2020-05-01)

Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis
by: Loraine Van Slyke FNP-C, et al.
Published: (2018-03-01)

New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate
by: Heba K. Ashour, et al.
Published: (2017-05-01)

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
by: Prinapori R, et al.
Published: (2015-08-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-07-01)

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
by: Anna Gidari, et al.
Published: (2023-12-01)

Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives
by: James AM, et al.
Published: (2013-08-01)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
by: Dorward, J, et al.
Published: (2023)

Safety and Efficacy of Fixed Drug Combination Tenofovir, Lamivudine and Efavirenz to Prevent Transmission of HIV
by: Pramendra Sirohi, et al.
Published: (2021-07-01)

A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention
by: Erick Leung, et al.
Published: (2023-12-01)

Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
by: Javier Perez Stachowski, et al.
Published: (2022-08-01)

Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance
by: Yu-Yu Hsiao, et al.
Published: (2021-08-01)

Assessment of treatment outcomes for HIV Positives transitioned from Tenofovir/Lamivudine/Efavirenz to Tenofovir/Lamivudine/Dolutegravir in a Nigerian Tertiary Hospital
by: Omobola Yetunde Ojo, et al.
Published: (2023-12-01)